Literature DB >> 25618127

The lifetime prevalence of anxiety disorders among patients with irritable bowel syndrome.

Magdalena Grzesiak1, Jan A Beszłej1, Agata Mulak2, Marcin Szechiński1, Monika Szewczuk-Bogusławska1, Ewa Waszczuk2, Monika Kantorska1, Dorota Frydecka1.   

Abstract

BACKGROUND: The prevalence of irritable bowel syndrome (IBS), the most common functional gastrointestinal disorder, ranges from 10% to 20% in the general population. It is estimated that from 40% to 90% of persons with a diagnosis of IBS suffer from mental disorders, mainly anxiety and depressive disorders.
OBJECTIVES: The aim of the study was to assess the lifetime prevalence of anxiety disorders in IBS patients and to compare it with the prevalence of these disorders in a control group of patients with gastroesophageal reflux disease (GERD).
MATERIAL AND METHODS: The study included 106 patients with IBS and 53 patients with GERD. IBS was diagnosed according to the Rome II criteria after a basic evaluation to exclude an organic disease. Anxiety disorders were diagnosed using the Composite International Diagnostic Interview (CIDI) in accordance with ICD-10 diagnostic criteria.
RESULTS: Anxiety disorders during the patient's lifetime were diagnosed in 50 IBS patients (47%). Specific phobias occurred in 23.5% of them, social phobias in 10.4%, generalized anxiety disorder in 10.4%, panic disorder in 3.8% and agoraphobia in 8.5%. In the control group with GERD, anxiety disorders during the subject's lifetime were diagnosed in 30% of the group. The difference in the prevalence of anxiety disorders between patients with IBS and GERD was statistically significant (p<0.05).
CONCLUSIONS: The lifetime prevalence of anxiety disorders in IBS patients was higher than in the control group with GERD (47% vs. 30%). The prevalence rate of anxiety disorders in the control group with GERD was similar to the prevalence rate in the general population.

Entities:  

Mesh:

Year:  2014        PMID: 25618127     DOI: 10.17219/acem/37356

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  7 in total

Review 1.  The mucosal immune system: master regulator of bidirectional gut-brain communications.

Authors:  Nick Powell; Marjorie M Walker; Nicholas J Talley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-01-18       Impact factor: 46.802

2.  Serotonin-Related Gene Variants in Patients with Irritable Bowel Syndrome and Depressive or Anxiety Disorders.

Authors:  Magdalena Grzesiak; Jan Aleksander Beszłej; Ewa Waszczuk; Marcin Szechiński; Monika Szewczuk-Bogusławska; Dorota Frydecka; Tadeusz Dobosz; Anna Jonkisz; Arleta Lebioda; Małgorzata Małodobra; Agata Mulak
Journal:  Gastroenterol Res Pract       Date:  2017-08-16       Impact factor: 2.260

3.  Against the Stream: Generalised anxiety disorder (GAD) - a redundant diagnosis.

Authors:  Peter Tyrer
Journal:  BJPsych Bull       Date:  2018-03-01

4.  Association of anxiety-depressive disorders with irritable bowel syndrome among patients attending a rural family practice center: a comparative cross-sectional study.

Authors:  Alaa Adel Mohammed; Heba Ahmed Moustafa; Hebatallah Nour-Eldein; Rabab Atta Saudi
Journal:  Gen Psychiatr       Date:  2021-12-13

5.  Understanding symptom burden and attitudes to irritable bowel syndrome with diarrhoea: Results from patient and healthcare professional surveys.

Authors:  Hans Törnblom; Richard Goosey; Gwen Wiseman; Stephen Baker; Anton Emmanuel
Journal:  United European Gastroenterol J       Date:  2018-07-09       Impact factor: 4.623

6.  Connecting Our Gut Feeling and How Our Gut Feels: The Role of Well-being Attributes in Irritable Bowel Syndrome.

Authors:  Ashkan Farhadi; Dwaine Banton; Laurie Keefer
Journal:  J Neurogastroenterol Motil       Date:  2018-04-30       Impact factor: 4.924

7.  A Comprehensive Look at Irritable Bowel Syndrome and its Associated Factors Considering the Rome IV Criteria: A Penalized Smoothly Clipped Absolute Deviation Regression Approach in the Pars Cohort Study.

Authors:  Peyman Arasteh; Najmeh Maharlouei; Seyed Sajjad Eghbali; Mitra Amini; Kamran B Lankarani; Reza Malekzadeh
Journal:  Middle East J Dig Dis       Date:  2018-06-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.